MedTrace Logo

Study Comparing Onyx and TRUFILL in Brain Arteriovenous Malformations (AVMs)

NCT00857662 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2023-10-27

No results posted yet for this study

Summary

Test whether AVMs treated with Onyx is equivalent to treatment with n-BCA. Success is defined as an AVM size reduction greater than 50%

Conditions

  • Brain Arteriovenous Malformations

Interventions

DEVICE

Onyx

Embolization

DEVICE

TRUFILL

Embolization

Sponsors & Collaborators

  • Micro Therapeutics Inc.

    collaborator INDUSTRY

  • Medtronic Neurovascular Clinical Affairs

    lead INDUSTRY

Principal Investigators

  • Gary Duckwiler, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2003-04-30
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857662 on ClinicalTrials.gov